Holen Sie sich die Stockscreener-App
25.05
1.24%
-0.3048
Schlusskurs vom Vortag:
$25.35
Offen:
$25.44
24-Stunden-Volumen:
2.84M
Relative Volume:
0.28
Marktkapitalisierung:
$9.74B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-2.8689
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
-6.76%
1M Leistung:
-1.16%
6M Leistung:
-10.01%
1J Leistung:
-54.66%
1-Tages-Spanne:
$24.92
$25.55
1-Wochen-Bereich:
$24.92
$27.37
52-Wochen-Spanne:
$23.15
$56.70
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.05 | 9.90B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.38 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
656.85 | 69.37B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.09 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
830.38 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.18 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
US health agency fires official who opposed mRNA Covid shots - MarketScreener
New COVID vaccine says it’s for the ‘senior class’ — does it reduce side effects? - San Francisco Chronicle
AlphaQuest LLC Increases Position in Moderna, Inc. $MRNA - MarketBeat
Ethic Inc. Purchases 10,325 Shares of Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock trades before earningsWatch List & Community Verified Swing Trade Signals - newser.com
Why Moderna Inc. stock is a value investor pick2025 Retail Activity & Stock Portfolio Risk Management - Fundação Cultural do Pará
Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment - TipRanks
Will Moderna Inc. stock see insider buyingJuly 2025 Snapshot & Low Drawdown Trading Techniques - Fundação Cultural do Pará
Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud - Law360
What’s next for Moderna Inc. stock priceJuly 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Best data tools to analyze Moderna Inc. stockDollar Strength & Growth Oriented Trade Recommendations - newser.com
Using economic indicators to assess Moderna Inc. potentialTrade Ideas & Real-Time Price Movement Reports - newser.com
Is Moderna Inc. meeting your algorithmic filter criteriaJuly 2025 Closing Moves & Real-Time Buy Zone Alerts - newser.com
D.A. Davidson & CO. Purchases 62,778 Shares of Moderna, Inc. $MRNA - MarketBeat
Why Moderna Inc. stock is favored by top institutionsJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
Is Moderna Inc. stock in correction or buying zonePortfolio Return Summary & Long-Term Capital Growth Ideas - newser.com
Analysts Set Expectations for Moderna FY2026 Earnings - MarketBeat
FY2026 EPS Estimates for Moderna Lowered by Analyst - MarketBeat
Equities Analysts Issue Forecasts for Moderna Q3 Earnings - MarketBeat
Moderna (NASDAQ:MRNA) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Is it too late to sell Moderna Inc.IPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Moderna scraps mRNA vaccine in congenital CMV on trial failure - Medical Dialogues
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Daily News Journal
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
How moving averages guide Moderna Inc. trading2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com
Moderna to Host Investor Event – Analyst Day - Shelby Star
Moderna Named a Top Employer by Science for Eleventh Consecutive Year - Bluffton Today
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Pueblo Chieftain
Moderna (MRNA) Outperforms Broader Market: What You Need to Know - Yahoo Finance
JPMorgan Chase & Co. Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00 - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap Down Following Analyst Downgrade - MarketBeat
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - The Daily Jeffersonian
UBS Maintains Moderna (MRNA) Buy Recommendation - Nasdaq
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - The Holland Sentinel
How Investors May Respond To Moderna (MRNA) Halting Development of mRNA-1647 CMV Vaccine - Yahoo Finance
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Asheville Citizen Times
Moderna, Inc. (MRNA) Stock Forecasts - Yahoo Finance
UBS Adjusts Moderna (MRNA) Price Target to $40, Maintains Buy Ra - GuruFocus
Moderna’s cytomegalovirus vaccine fails a phase III - BioWorld MedTech
Moderna Flunks Pivotal CMV Trial, But Read-Through Unlikely - Citeline News & Insights
Moderna (NASDAQ: MRNA) earns 11th straight Top Employer ranking in Science’s 2025 survey - Stock Titan
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):